Research and Markets: IMS Pricing & Reimbursement Concise Guide: United Kingdom

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8734fa/ims_pricing_reim) has announced the addition of the "IMS Pricing & Reimbursement Concise Guide: United Kingdom" report to their offering.

The P&R Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Key Topics Covered:

Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding

Pricing

  • Prescription Drugs
  • 2009 Pprs
  • Generic Drugs
  • Hospital Drugs
  • Otc Drugs

Reimbursement

  • Admission To Reimbursement
  • Automatic Reimbursement And Exclusions
  • Local Funding Decisions
  • Nice: Fourth Hurdle
  • Patient Access Schemes
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes In Reimbursement Status
  • Changes In Reimbursement Prices
  • Pprs Price Cuts And Increases
  • Pprs Flexible Pricing
  • Pprs Ad Hoc Price Increases
  • Category M

Pharmacoeconomics

  • Pharmacoeconomic Requirements
  • Nice
  • Smc

Price Build Up

  • Wholesalers
  • Branded Drugs
  • Generics And Parallel Imports
  • Retail Pharmacies
  • Dispensing Fee
  • Branded Drugs
  • Generic Drugs
  • Parallel Imports
  • Pharmacy Clawback
  • Zero Discounted Drugs
  • Background
  • Dispensing Doctors
  • Sales Tax

Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-Payments
  • Prescribing Controls
  • Budgets
  • Prescribing Incentive Schemes

For more information visit http://www.researchandmarkets.com/research/8734fa/ims_pricing_reim

Source: IMS Health



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.